What question did this study set out to answer?

To investigate the chronopharmacological profile and anticoagulant efficacy of once-daily curative doses of low molecular weight heparin administered in the morning versus the evening.

January 1, 1995Thrombosis and Haemostasis

Chrono-Pharmacological Study of Once Daily Curative Dose of a Low Molecular Weight Heparin (200IU antiXa/kg of Dalteparin) in Ten Healthy Volunteers

View Full Paper

Ask AI

Bookmark

Why the study?

Does evening administration of dalteparin alter its biological anticoagulant effect compared to morning administration in healthy volunteers?

Population

10 healthy volunteers

Comparison

Subcutaneous injection of 200 IU antiXa/kg of… vs Subcutaneous injection of 200 IU antiXa/kg of…

Design

Other, open

Follow-up

Three 24-hour cycles separated by 7-day wash-out intervals

Authors

PMPatrick MismettiGeneral / Preventive / Lipids JRJ. ReynaudCentre Hospitalier Universitaire de Saint-Étienne BTB. Tardy-PoncetUniversité Claude Bernard Lyon 1

Discussion

Member takes

Implication

Evening dalteparin may enhance anticoagulant parameters in volunteers; leaves open whether chrono-dosing improves outcomes or warrants trials in patients.

Key Points

To investigate the chronopharmacological profile and anticoagulant efficacy of once-daily curative doses of low molecular weight heparin administered in the morning versus the evening.
Open three-period crossover study conducted in 10 healthy volunteers across three 24-hour cycles separated by 7-day washout periods.
Interventions comprised a control cycle without injection and two cycles with subcutaneous injection of 200 IU antiXa/kg dalteparin administered at 8 a.m. or 8 p.m.
Coagulation parameters were evaluated using maximal values and area under the curve measurements.
Activated partial thromboplastin time, thrombin time, prothrombin time, and tissue factor pathway inhibitor were significantly higher following the 8 p.m. injection compared to the 8 a.m. injection (p < 0.05).
Anti-factor Xa activity exhibited no statistically significant chronopharmacological variation between morning and evening injections.

Structured PICO

Does evening administration of dalteparin alter its biological anticoagulant effect compared to morning administration in healthy volunteers?

Population

10 healthy volunteers

Intervention

Subcutaneous injection of 200 IU antiXa/kg of dalteparin at 8 p.m.

Comparator

Subcutaneous injection of 200 IU antiXa/kg of dalteparin at 8 a.m. and a control cycle without injection

Outcome

Parameters of heparin activity (maximal values and area under the curve for activated partial thromboplastin time [APTT], thrombin time [TT], prothrombin time [PT], tissue factor pathway inhibitor [TFPI], and anti factor Xa [AXa])surrogate

The biological anticoagulant effect of dalteparin appears to be higher when administered in the evening compared to the morning, suggesting a potential chrono-therapeutic approach.

Cite This Study

Mismetti et al. (1995) studied this question.

synapsesocial.com/papers/6a91232cefab70d99b73e92f https://doi.org/10.1055/s-0038-1649794

View Full Paper

Ask AI

Bookmark

Implication

Evening dalteparin may enhance anticoagulant parameters in volunteers; leaves open whether chrono-dosing improves outcomes or warrants trials in patients.

Chrono-Pharmacological Study of Once Daily Curative Dose of a Low Molecular Weight Heparin (200IU antiXa/kg of Dalteparin) in Ten Healthy Volunteers

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Chrono-Pharmacological Study of Once Daily Curative Dose of a Low Molecular Weight Heparin (200IU antiXa/kg of Dalteparin) in Ten Healthy Volunteers

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider